Detalles de la búsqueda
1.
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
Int J Cancer
; 139(1): 177-86, 2016 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26891420
Resultados
1 -
1
de 1
1
Próxima >
>>